DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$29.06M

FY 2025 · Annual

Investing Cash Flow

-$2.19M

FY 2025 · Annual

Financing Cash Flow

$43.88M

FY 2025 · Annual

+265.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Depreciation & Amortization24K25K30K39K(899K)
Deferred Income Tax00000
Stock-Based Compensation1.56M1.5M1.68M2.09M3.85M
Change in Working Capital(461K)585K93K1.51M675K
Accounts Receivables210K48K(287K)133K(22K)
Inventory00000
Accounts Payables(590K)225K192K14K535K
Other Working Capital(81K)312K188K1.37M162K
Other Non-Cash Items219K53K(1.15M)(1.27M)82K
Operating Cash Flow(12.25M)(11.51M)(18.73M)(22.08M)(29.06M)
Capital Expenditures(22K)(81K)(24K)(25K)(40K)
Acquisitions (Net)00000
Purchases of Investments(69.81M)(45.68M)(69.41M)(50.41M)(59.28M)
Sales of Investments49.3M57.3M51.14M59M57.13M
Other Investing Activities2K0000
Investing Cash Flow(20.54M)11.54M(18.3M)8.56M(2.19M)
Debt Repayment(6K)(6K)(6K)(9K)(10K)
Common Stock Issued29.85M036.85M11.75M44.29M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities244K00256K(400K)
Financing Cash Flow30.09M(6K)36.84M11.99M43.88M
Effect of Forex Changes00000
Net Change in Cash(2.7M)21K(185K)(1.52M)12.62M
Free Cash Flow(12.27M)(11.59M)(18.75M)(22.1M)(29.1M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$32.8M
+ D&A-$899.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$675.0K
+ Other Non-Cash$82.0K
= Operating Cash Flow-$29.1M
- Capex-$40.0K
= Free Cash Flow-$29.1M

Analysis

FY2025 free cash flow is -$29.1M. FCF conversion is 88.8% of net income. Operating cash flow was -$29.1M, with capex of -$40.0K. The largest bridge item is Stock-Based Comp at $3.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipAug 12, 2026
S-8S-8 filingAug 11, 2026
10-QQuarterly reportAug 10, 2026

Does DMAC generate free cash flow?

DiaMedica Therapeutics Inc. (DMAC) generated -$29.10M of free cash flow in fiscal 2025.

How much operating cash flow does DMAC produce?

Operating cash flow was -$29.06M, before capital expenditures of $40,000.00.